Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 1, 2010, Pages 51-54

  Schorr, Mario Casales ^a   Pedrini, José Luiz ^b   Savaris, Ricardo Francalacci ^c   Zettler, Cláudio Galleano ^d  

^a Irmandade da Santa Casa de Misericórdia de Porto Alegre ^*  (Brazil)

^b Hospital Nossa Senhora da Conceição Grupo Hospitalar Conceição   (Italy)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d Fundação Faculdade Federal de Ciências Médicas de Porto Alegre   (Brazil)

Author keywords

Breast cancer; Estrogen receptor; HER 2 neu; P53; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, DUCTAL, BREAST; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 76149103555     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181acaded     Document Type: Article

References (20)

1. Brasil: Ministério da Saú de. Incidência de Câncer no Brasil: Estimativa 2008. Brasília, Instituto Nacional de Câncer, 2007.
2. Allred DC, Wu Y, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 2008;14:370-378.
3. Tang P, Hajdu SI, Lyman GH. Ductal carcinoma in situ: a review of recent advances. Curr Opin Obstet Gynecol. 2007;19:63-67.
4. Giardina C, Serio G, Lepore G, et al. Pure ductal carcinoma in situ and in situ component of ductal invasive carcinoma of the breast. A preliminary morphometric study. J Exp Clin Cancer Res. 2003; 22:279-288.
5. Steinman S, Wang J, Bourne P, et al. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007; 37:127-134.
6. Pedrini JL, Pedrini M, Savaris RF, et al. Reassessing tumor markers in local recurrences of breast cancer: a new insight. Med Sci Monit. 2004;10:BR462-BR467.
7. Ferrero-Pous M, Trassard M, Le Doussal V, et al. Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol. 2001;9:267-275.
8. Pinto AE, Andre S, Laranjeira C, et al. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology. 2005;37:45-50.
9. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of Hercep test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987.
10. Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res. 1999;5:4079-4084.
11. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312.
12. Mylonas I, Makovitzky J, Jeschke U, et al. Expression of HER-2/ neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with Ductal Carcinoma In Situ (DCIS) versus invasive breast cancer alone. Anticancer Res. 2005;25:1719-1723.
13. Schuetz CS, Bonin M, Clare SE, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res. 2006;66:5278-5286.
14. Moriya T, Silverberg SG. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma. Cancer. 1994;74:2972-2978.
15. Porter DA, Krop IE, Nasser S, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 2001;61:5697-5702.
16. Porter D, Lahti-Domenici J, Keshaviah A, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1:362-375.
17. Seth A, Kitching R, Landberg G, et al. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer Res. 2003;23:2043-2051.
18. Hoque A, Menter DG, Sahin AA, et al. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:153-154.
19. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96:906-920.
20. Meijnen P, Peterse JL, Antonini N, et al. Immunohistochemical categorization of ductal carcinoma in situ of the breast. Br J Cancer. 2008;98:137-142.